Share on StockTwits

Opko Health (NYSE:OPK) CEO Phillip Md Et Al Frost bought 63,000 shares of the company’s stock in a transaction that occurred on Tuesday, August 12th. The stock was purchased at an average cost of $8.97 per share, with a total value of $565,110.00. Following the transaction, the chief executive officer now directly owns 2,012,377 shares in the company, valued at approximately $18,051,022. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

Opko Health (NYSE:OPK) remained flat at $9.08 during trading on Wednesday. 1,149,962 shares of the company’s stock traded hands. Opko Health has a 52 week low of $7.32 and a 52 week high of $12.95. The stock’s 50-day moving average is $8.88 and its 200-day moving average is $8.78. The company’s market cap is $3.859 billion. Opko Health also was the target of unusually large options trading activity on Monday. Stock investors acquired 2,916 put options on the company. This represents an increase of 286% compared to the average daily volume of 755 put options.

Opko Health (NYSE:OPK) last released its earnings data on Monday, August 11th. The company reported ($0.06) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.03. The company had revenue of $23.50 million for the quarter, compared to the consensus estimate of $23.70 million. During the same quarter last year, the company posted ($0.01) earnings per share. Opko Health’s revenue was down 1.3% compared to the same quarter last year. On average, analysts predict that Opko Health will post $-0.36 earnings per share for the current fiscal year.

A number of analysts have recently weighed in on OPK shares. Analysts at Jefferies Group reiterated a “buy” rating on shares of Opko Health in a research note on Wednesday. They now have a $10.50 price target on the stock, down previously from $11.00. Finally, analysts at TheStreet upgraded shares of Opko Health from a “sell” rating to a “hold” rating in a research note on Friday, May 30th. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $12.00.

OPKO Health, Inc (NYSE:OPK) is a multi-national biopharmaceutical and diagnostics company.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.